| Name | Title | Contact Details |
|---|
San Antonio Behavioral Healthcare Hospital is a trusted mental health treatment facility location in San Antonio, TX
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT`s head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).
At Senderra, Patients are people. It`s that simple. We are a specialty pharmacy, but that is where our work begins. We believe success lies in service to others. For this reason, we are dedicated to never losing sight of the people. We believe in the power of technology and data as catalysts to transform and improve processes. Technology is a tool to make our lives easier. For this reason, Senderra invests in our unique technology-driven platform in order to perform best at every turn. Finally, we believe in improved outcomes, no matter with whom we work. That includes Patients, Prescribers, Pharma and Payors. Improving outcomes means we strive to make the kinds of differences that matter.
vTv Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.